• Mark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell Anemia

  • Oct 20 2023
  • Length: 33 mins
  • Podcast
  • 5.0 out of 5 stars (1 rating)
Mark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell Anemia By cover art

Mark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell Anemia

Listen for free

View show details

  • Summary

  • Dr. Mark DeWitt Ph.D., Associate Director at Mammoth Biosciences, and Dr. Don Kohn M.D., distinguished professor and Director of the UCLA Human Gene and Cell Therapy Program and CIRM grantee sat down with us to discuss their latest clinical trials to cure sickle cell anemia, how synthetic guides accelerated their journey from the bench to the clinic, and their experience in the cell and gene therapy space.
    Show more Show less
Biological Sciences
Show more Show less

What listeners say about Mark DeWitt and Don Kohn Discuss Their ex vivo CRISPR-based Therapy to Cure Sickle Cell Anemia

Average customer ratings
Overall
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0
Performance
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0
Story
  • 5 out of 5 stars
  • 5 Stars
    1
  • 4 Stars
    0
  • 3 Stars
    0
  • 2 Stars
    0
  • 1 Stars
    0

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
Sort by:
Filter by:
  • Overall
    5 out of 5 stars
  • Performance
    5 out of 5 stars
  • Story
    5 out of 5 stars
Profile Image for L. Rodgers

Cures for sickle Cell

Brilliantly executed - thank you this is so hopeful. I am hoping for a cure for Huntingtons disease.

Report this

Something went wrong. Please try again in a few minutes.

You voted on this review!

You reported this review!